stockportfolio.pro
BAX vs TECH: Which Stock Is the Better Buy?
Baxter International Inc. and Bio-Techne Corporation side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
AI verdict — BAX vs TECH, read from the filings
The stronger business, the cheaper stock, and the risks — synthesised from both companies’ SEC filings, every figure computed not guessed. Not investment advice.
| Baxter International Inc. (BAX) | Bio-Techne Corporation (TECH) | |
|---|---|---|
| Market cap | $11.7B | $11.2B |
| Revenue (latest FY) | $11.24B | $1.22B |
| Net income (latest FY) | $-957.00M | $73.40M |
| Revenue growth (5y CAGR) | -0.7% | 10.5% |
| Net margin | -8.5% | 6.0% |
| Return on equity | -15.6% | 3.8% |
| P/E ratio | — | 103.0 |
| Dividend yield | 0.9% | 0.4% |
| Profitable years (of last 10) | 7 | 10 |
| Positive free cash flow | Yes | Yes |
See the full BAX vs TECH breakdown
Both companies across 19 years of income statement, balance sheet and cash flow — with ratios, health checks and Ask, the SEC-grounded research assistant. Free, no account needed.
Open BAX's full financials → Open TECH's full financials →More comparisons
Frequently asked questions
Which is bigger, BAX or TECH?
Baxter International Inc. is larger by market capitalization — $11.7B versus $11.2B.
Which grows faster, BAX or TECH?
Over the last five fiscal years, Bio-Techne Corporation grew revenue faster — 10.5%/yr versus -0.7%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.